Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 1
2012 2
2013 3
2014 5
2015 4
2016 2
2017 2
2018 5
2019 2
2020 4
2021 5
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Dendritic Cell-Based Immunotherapy in Lung Cancer.
Stevens D, Ingels J, Van Lint S, Vandekerckhove B, Vermaelen K. Stevens D, et al. Among authors: van lint s. Front Immunol. 2021 Feb 12;11:620374. doi: 10.3389/fimmu.2020.620374. eCollection 2020. Front Immunol. 2021. PMID: 33679709 Free PMC article. Review.
mRNA in cancer immunotherapy: beyond a source of antigen.
Van Hoecke L, Verbeke R, Dewitte H, Lentacker I, Vermaelen K, Breckpot K, Van Lint S. Van Hoecke L, et al. Among authors: van lint s. Mol Cancer. 2021 Mar 3;20(1):48. doi: 10.1186/s12943-021-01329-3. Mol Cancer. 2021. PMID: 33658037 Free PMC article. Review.
The ReNAissanCe of mRNA-based cancer therapy.
Van Lint S, Renmans D, Broos K, Dewitte H, Lentacker I, Heirman C, Breckpot K, Thielemans K. Van Lint S, et al. Expert Rev Vaccines. 2015 Feb;14(2):235-51. doi: 10.1586/14760584.2015.957685. Epub 2014 Sep 29. Expert Rev Vaccines. 2015. PMID: 25263094 Review.
Targeting the tumor microenvironment to enhance antitumor immune responses.
Van der Jeught K, Bialkowski L, Daszkiewicz L, Broos K, Goyvaerts C, Renmans D, Van Lint S, Heirman C, Thielemans K, Breckpot K. Van der Jeught K, et al. Among authors: van lint s. Oncotarget. 2015 Jan 30;6(3):1359-81. doi: 10.18632/oncotarget.3204. Oncotarget. 2015. PMID: 25682197 Free PMC article. Review.
Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula.
Van Lint S, Wilgenhof S, Heirman C, Corthals J, Breckpot K, Bonehill A, Neyns B, Thielemans K. Van Lint S, et al. Cancer Immunol Immunother. 2014 Sep;63(9):959-67. doi: 10.1007/s00262-014-1558-3. Epub 2014 May 31. Cancer Immunol Immunother. 2014. PMID: 24878889 Free PMC article. Review.
Immunogenicity of targeted lentivectors.
Goyvaerts C, Kurt de G, Van Lint S, Heirman C, Van Ginderachter JA, De Baetselier P, Raes G, Thielemans K, Breckpot K. Goyvaerts C, et al. Among authors: van lint s. Oncotarget. 2014 Feb 15;5(3):704-15. doi: 10.18632/oncotarget.1680. Oncotarget. 2014. PMID: 24519916 Free PMC article.
Small-scale manufacturing of neoantigen-encoding messenger RNA for early-phase clinical trials.
Ingels J, De Cock L, Mayer RL, Devreker P, Weening K, Heyns K, Lootens N, De Smet S, Brusseel M, De Munter S, Pille M, Billiet L, Goetgeluk G, Bonte S, Jansen H, Lint SV, Leclercq G, Taghon T, Menten B, Vermaelen K, Impens F, Vandekerckhove B. Ingels J, et al. Among authors: lint sv. Cytotherapy. 2022 Feb;24(2):213-222. doi: 10.1016/j.jcyt.2021.08.005. Epub 2021 Oct 22. Cytotherapy. 2022. PMID: 34696961 Free article.
mRNA: delivering an antitumor message?
Van Lint S, Thielemans K, Breckpot K. Van Lint S, et al. Immunotherapy. 2011 May;3(5):605-7. doi: 10.2217/imt.11.28. Immunotherapy. 2011. PMID: 21554090
32 results